CVAC

CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, CV7202, an mRNA prophylactic targeting the rabies virus glycoprotein, has successfully completed its Phase 1 clinical evaluation. Additionally, CVSQIV, aimed at influenza, is also undergoing Phase 1 clinical trials. Further vaccine development efforts are directed towards lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza solution. Beyond its vaccine initiatives, CureVac is also engaged in developing RNA-based immunotherapies for cancer. For instance, CV8102, an immunotherapy, is currently undergoing Phase 1 trials for the treatment of cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma affecting the skin, head, and neck. The company was established in 2000 and operates from its main office in Tübingen, Germany.

Sector

Healthcare

Industry

Biotechnology

Country

DE

Employees

825

Website

curevac.com